SELLAS Life Sciences Group to Present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016

ZUG, Switzerland and NEW YORK, Jan. 5, 2016 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat cancers and central nervous system (CNS) diseases, today announced that Angelos M. Stergiou, M.D., Chief Executive Officer and Chairman of the Board, will present at the 34^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12^th, 2016 at 3:30p.m. Pacific Time at the Westin St. Francis in San Francisco, CA.  Dr. Stergiou's presentation will include a SELLAS Life Sciences Group corporate overview as well as clinical and business update.

About SELLAS Life Sciences Group

SELLAS Life Sciences is a development-stage biopharmaceutical company focused on innovative products to treat cancer and central nervous system (CNS) diseases. SELLAS has two Phase 2b- and 3-ready products poised to enter trials in Europe and the US in 2016, across multiple indications in cancer and CNS diseases, as well as an earlier-stage highly innovative cancer therapeutic.

SELLAS' WT1 vaccine, licensed from Memorial Sloan Kettering Cancer Center, is a cancer immunotherapeutic agent targeting a broad spectrum of hematologic cancers and solid tumor indications. This program will advance into Phase 3 trials in 2016 in Acute Myeloid Leukemia (AML) and Malignant Pleural Mesothelioma (MPM). SELLAS is also advancing a proprietary formulation of high-dose Zolpidem under the 505(b)(2) pathway to treat basal ganglia disorders, including Parkinson's disease and Progressive Supranuclear Palsy (PSP), which is the lead orphan indication. Zolpidem's mechanism of action and therapeutic effects in such CNS-related diseases have been demonstrated in several studies. SELLAS expects to initiate a Phase 2b/3 study of high-dose Zolpidem for PSP around 1H 2016. A third program is focused on SELLAS' TR1 product candidate, a novel fusion protein that supplies the normal wild type p53/p21 protein to cancer cells to trigger innate cell death mechanisms (apoptosis). The Company is advancing its TR1 program toward IND-enabling studies, with the goal of commencing Phase 1 testing in 2016 and reporting initial data in 2017.

SELLAS was founded in 2012 and is headquartered in Zug, Switzerland, with additional offices in New York City, NY, USA.

Contact:

For Investors:  
Ami Bavishi, Burns McClellan, +1 (212) 213-0006, [email protected]

For Media: 
David Moser, J.D., + 1 (813) 864-2571, [email protected]  
Justin Jackson, Burns McClellan, +1 (212) 213-0006, [email protected]

SOURCE SELLAS Life Sciences Group

Related Links

http://sellaslifesciences.com